ME Therapeutics Closes Over-Subscribed Private Placement
· Financial Post
VANCOUVER, British Columbia -- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”). Read More
Visit moryak.biz for more information.